PALI vs. PHIO, SNSE, FLGC, DWTX, TXMD, BCDA, PMCB, KPRX, TLPH, and BCTX
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Phio Pharmaceuticals (PHIO), Sensei Biotherapeutics (SNSE), Flora Growth (FLGC), Dogwood Therapeutics (DWTX), TherapeuticsMD (TXMD), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical products" industry.
Palisade Bio vs.
Palisade Bio (NASDAQ:PALI) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Phio Pharmaceuticals' return on equity of -134.57% beat Palisade Bio's return on equity.
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 3.3% of Palisade Bio shares are held by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Phio Pharmaceuticals received 27 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 63.79% of users gave Phio Pharmaceuticals an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote.
Palisade Bio presently has a consensus price target of $23.00, indicating a potential upside of 2,338.51%. Phio Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 139.52%. Given Palisade Bio's higher probable upside, research analysts plainly believe Palisade Bio is more favorable than Phio Pharmaceuticals.
Palisade Bio has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Phio Pharmaceuticals has lower revenue, but higher earnings than Palisade Bio. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phio Pharmaceuticals had 4 more articles in the media than Palisade Bio. MarketBeat recorded 7 mentions for Phio Pharmaceuticals and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.68 beat Phio Pharmaceuticals' score of 0.13 indicating that Palisade Bio is being referred to more favorably in the media.
Summary
Phio Pharmaceuticals beats Palisade Bio on 9 of the 15 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PALI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PALI Stock Alerts